Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells. - Wikidata - wikimedia - TriplyDB

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells.

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells.

http://www.wikidata.org/entity/Q37388994

about

The in vivo kinetics of RNA polymerase II elongation during co-transcriptional splicing Modulating splicing with small molecular inhibitors of the spliceosome Defects in spliceosomal machinery: a new pathway of leukaemogenesis Alternative splicing for diseases, cancers, drugs, and databases smFRET studies of the 'encounter' complexes and subsequent intermediate states that regulate the selectivity of ligand binding Influenza Virus mRNA Trafficking Through Host Nuclear Speckles.Inhibition of U4 snRNA in human cells causes the stable retention of polyadenylated pre-mRNA in the nucleus.Multivalent peptidic linker enables identification of preferred sites of conjugation for a potent thialanstatin antibody drug conjugate Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.The Use of 3,5,4'-Tri-O-acetylresveratrol as a Potential Pro-drug for Resveratrol Protects Mice from γ-Irradiation-Induced Death.Spliceostatin A inhibits spliceosome assembly subsequent to prespliceosome formation.Pre-mRNA splicing is a determinant of nucleosome organization Identification of small molecule inhibitors of pre-mRNA splicing.Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.A quantitative high-throughput in vitro splicing assay identifies inhibitors of spliceosome catalysis.Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.Small Molecule Modulators of Pre-mRNA Splicing in Cancer Therapy Ruthenium-Catalyzed Olefin Metathesis after Tetra-n-butylammonium Fluoride-Mediated Desilylation.Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages Targeting RNA splicing for disease therapy.Regulation of primary response genes in B cells.Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43 Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs.Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.Pre-mRNA splicing in disease and therapeutics.The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms.Splicing factor mutations and cancer.Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.Histone H3K4 trimethylation: dynamic interplay with pre-mRNA splicing.Biosynthesis of polyketides by trans-AT polyketide synthases.Discoveries, target identifications, and biological applications of natural products that inhibit splicing factor 3B subunit 1.Alternative splicing: the pledge, the turn, and the prestige : The key role of alternative splicing in human biological systems.The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1.Splicing enhances recruitment of methyltransferase HYPB/Setd2 and methylation of histone H3 Lys36.Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing.Total RNA-seq to identify pharmacological effects on specific stages of mRNA synthesis.Expression levels of SF3B3 correlate with prognosis and endocrine resistance in estrogen receptor-positive breast cancer.

P2860

Q21090175-13012EC0-85D7-462A-B9F4-69286C3CA430 Q26738664-8E90CE02-F8AE-4458-A334-2A90285926BF Q26823040-807A5775-520F-4898-8C2B-A2791C036756 Q26852848-25CE82B1-0E52-4BC8-8834-CFCB66C66B04 Q26864185-A246C5CD-1F2D-4360-A7F8-6A4920D9C6AC Q30775411-F3D13697-8ED5-4A17-B76D-37A9820C5152 Q33567881-5DBBD01F-E05F-4228-89C2-A5E297F53C0F Q33739302-0A7F25F5-DA2E-442A-9599-E7742E5D6E03 Q34047259-6EF42F14-E743-4EF6-9359-8A6F1D5EE047 Q34206752-75D01CDD-425A-4BDB-AE5D-D8340BEF1936 Q34246700-5AE63CC9-512C-4ADF-9957-F6D6A6892896 Q34551455-CFFB6799-96C1-4676-88A2-F09051542840 Q35301222-5A52F872-54E1-415A-903C-A8D55FC128F9 Q35619558-9095CE5F-4C88-4B22-9391-712132DCB1A5 Q35826664-647A093A-AB18-4089-9764-2160FD22A59E Q35891380-B3D65514-0610-4B4E-BF29-F91A9E7DBED1 Q36333518-5CD18E56-0CB9-4110-9A2A-022B1D5FD416 Q36447664-B377F16B-779A-4B16-B023-F5FA30573FA3 Q36485554-20BF71B0-2EAE-4E61-BCA8-69E12A6F506D Q36485574-6863548A-E863-44B0-ABED-0A5E9D259CC6 Q36566585-0B98EBC8-CC48-4D8D-A9BB-D85639876B71 Q36780738-34A07FD9-91CD-40D9-BD55-4349D40DC680 Q36873605-44710770-617F-43A5-91B2-B11E7AC938C6 Q36966213-0828E164-F8F2-4834-8A92-2EF9D8A07A5A Q37511674-F37BC09C-C6AA-4FD3-9591-E5BA787F3966 Q38017093-5E255E9D-9262-4129-850C-D1424D3B1DE7 Q38028093-A99AFCE0-CD1F-41FB-A9F9-EDC712D0BD76 Q38033985-F9E27D92-ACE7-45A6-804B-71209FF4F286 Q38060535-B5D19318-F612-41EA-A92B-7B65F3DFC3A3 Q38187632-95E8DD33-37D3-41F8-B010-C43458459472 Q38286217-31A54C15-5BAF-43FF-BE09-880FBDF515E5 Q38583533-9F0C8C72-2CBC-414C-96B4-F8F2D742195E Q38675125-B54A583E-2C34-47EC-9234-F6EC1A93AFE6 Q38712211-06B62D7C-122C-4B04-B889-1F9CEF33183C Q38735423-8224DFE4-A13A-4DD3-B515-774223854A91 Q38826234-AAE8E512-96DD-4A9F-9E8D-25349FFB262A Q39500409-9A6AD7CE-6E78-43D0-9DF2-B385A305B25C Q39587350-AF1854B3-21B4-4375-92EF-DAA3092B9725 Q42775893-41A5DE86-60C0-4D54-AD4E-0C7CEC347C08 Q46189717-E8233241-3B27-404B-B09A-234B9F39B4C8

P2860

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells.

http://www.wikidata.org/entity/Q37388994

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 11 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@en

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@nl

type

label

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@en

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@nl

prefLabel

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@en

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@nl

P1433

Q37388994-30B8A1B1-D2DA-4EB1-8748-3F8F3FD95E89

P1476

Q37388994-735F6103-8B44-4319-B9C4-E2FEE1E7CC74

P2093

Q37388994-13545E66-D7D4-43CA-A6C1-FCA194F5C52B

Q37388994-15101CC6-B1F6-4E41-A49D-92B31F0A5335

Q37388994-29765CA2-3E98-4FBA-A277-157A4DC2DE47

Q37388994-60237413-C26B-4FEA-AF64-131D163678D0

Q37388994-62C852D2-4919-4C03-9DD1-AAE18F36CD3C

Q37388994-6BB46580-D3B7-43B3-A49C-22FB126A324A

Q37388994-71EFDF43-5F63-4FE7-9D05-DC4521540749

Q37388994-8A75EE2E-6BAB-4540-BD92-5A8043A69A33

Q37388994-9CD00AF0-5F64-4081-AD92-256B15C983CF

Q37388994-C6866B64-661C-439F-BA73-86F609897ADA

P2860

Q37388994-058DF935-5529-4F26-9129-01B9837DFB08

Q37388994-09AB8A6A-184E-44CB-904D-C437E16EF086

Q37388994-0E808990-6021-4F68-A499-E4F7E178E412

Q37388994-12B347E2-4EAA-48EB-AFA0-876F53793899

Q37388994-141B5B85-D7D3-4417-A197-F93A9491E1B9

Q37388994-1551FB43-7323-44B4-A68C-BE629A449B3C

Q37388994-160F4518-1A6F-41B9-97F1-7909AE0D7653

Q37388994-16D522FA-E9EB-4566-8E51-4062A41E0293

Q37388994-1BCBCE41-807C-4DF2-AE93-F3FE8AB5EACA

Q37388994-232039E4-C248-437D-BE86-FE1083347E55

P304

Q37388994-53E68C60-4C85-4E9F-886A-2055202B008A

P31

Q37388994-66ADA6FD-8B82-4495-80C1-3C2A8AC55D7E

P356

Q37388994-B0379515-7BD6-4CA5-A2DB-091CF77A2DD1

P433

Q37388994-983A056D-0E92-4CD0-95D0-371C13051CB6

P478

Q37388994-D9DBBCA8-FF1F-4DFC-B388-2221E3CF4EBC

P577

Q37388994-0983ADEE-301A-47E2-8D82-D4D8A98A47A1

P5875

Q37388994-A7819AC7-AF3E-4884-AD94-C146688560B4

P698

Q37388994-5E0A6BAE-3CCE-4070-A02D-904AB1613047

P921

Q37388994-6B6CC24F-4DDF-42AA-8A9F-D7766DB6B3A7

P932

Q37388994-29124FED-04D7-4042-998A-7CFA9BE68B41

P356

1535-7163.MCT-09-0051

P1433

Molecular Cancer Therapeutics

P1476

Meayamycin inhibits pre-messen ...... nst multidrug-resistant cells.

@en

P2093

Andreas Vogt

http://www.w3.org/2001/XMLSchema#string

Billy W Day

http://www.w3.org/2001/XMLSchema#string

Brian J Albert

http://www.w3.org/2001/XMLSchema#string

Kazunori Koide

http://www.w3.org/2001/XMLSchema#string

Kristine O'Brien

http://www.w3.org/2001/XMLSchema#string

Melissa J Moore

http://www.w3.org/2001/XMLSchema#string

Miaosheng Li

http://www.w3.org/2001/XMLSchema#string

Nancy L Czaicki

http://www.w3.org/2001/XMLSchema#string

Paula J Grabowski

http://www.w3.org/2001/XMLSchema#string

Peter A McPherson

http://www.w3.org/2001/XMLSchema#string

P2860

Protein modularity of alternatively spliced exons is associated with tissue-specific regulation of alternative splicing.

Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei

Exon silencing by UAGG motifs in response to neuronal excitation

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

Targeting multidrug resistance in cancer

Interactions between small nuclear ribonucleoprotein particles in formation of spliceosomes

Cellular analysis of disorazole C and structure-activity relationship of analogs of the natural product.

Better conditions for mammalian in vitro splicing provided by acetate and glutamate as potassium counterions

Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors.

P53 mRNA controls p53 activity by managing Mdm2 functions.

P304

2308-2318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0051

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26733260

http://www.w3.org/2001/XMLSchema#string

P698

19671752

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

2762647

http://www.w3.org/2001/XMLSchema#string